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THE ROLE OF β–ARRESTIN IN AGONIST-INDUCED DOWN-REGULATION 
OF THE M1 mAChR 
Chair:  Darrell A. Jackson  
 
 
  G protein-coupled receptors (GPCRs) are the largest family of integral membrane 
receptors.  They mediate diverse cell signaling pathways and therefore are currently the 
target for 50% of all prescribed drugs.  Cells utilize these receptors to transduce 
extracellular stimuli across the plasma membrane and activate intracellular G proteins, 
which then initiate second messenger system cascades.  GPCR signaling is the focus of 
much research.  One member of this large family of membrane receptors is the 
muscarinic acetylcholine receptor (mAChR).  Five mAChR subtypes exist and are 
designated as M1-M5.  The goal of this project was to determine whether β-arrestin is 
critical in mediating agonist-induced down-regulation of the M1 mAChR.  Further, the 
objective of this proposal is to examine whether ubiquitination of β-arrestin is necessary 
for mediating agonist-induced down-regulation of the M1 mAChR.  Substantial research 
has focused on the cytosolic protein β-arrestin for its key role in the desensitization of 
most GPCRs.  More recently β-arrestin has been indicated in regulating other signaling 
within the cell.  Ubiquitination of proteins, in particular β-arrestin, has been emerging as 
another major player for targeting receptors for not only degradation but other signaling 
pathways as well. This project employed mouse embryonic fibroblast (MEF) cells for 
investigating how β-arrestin is involved with the down-regulation of M1 mAChR.  MEF 
cells were chosen for this study because they do not have endogenous mAChR 
expression.  The MEF cells lacking both isoforms of β-arrestin (KO1/2) were unable to 
down-regulate the receptor, but single knockouts (KO1 and KO2) could still down-
regulate the receptor.  Constitutively ubiquitinated β-arrestin facilitated agonist-induced 
down-regulation.  These results indicate that agonist-induced down-regulation of the M1 
mAChR is β-arrestin dependent and is mediated by ubiquitination of β-arrestin.   
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Figure 1. Time-course of agonist-induced down-regulation of the M1 mAChR in 
MEF cells.  MEF cells were transiently transfected with eGFP-M1 mAChR.  Cells were 
treated with 1 mM carbachol 24 hr after transfection for the time indicated on the x-axis. 
Down-regulation was determined by measuring the binding of the membrane permeable 
muscarinic antagonist [3H]-L-quinuclidinyl benzilate (QNB).  The number of receptors 
remaining following stimulation as compared to number of receptors from non-stimulated 
controls determined the percent down-regulation. A. Time-course in MEF wild type 
(WT) and MEF KO1/2 cells.  In MEF WT cells, 0 hr vs. 6 hr was not significantly 
different.  0 hr compared to 12 hr was significant (p<0.05) and 12 hr vs. 18 hr was not 
significantly different.  The maximal down-regulation of ~ 50% occurred at 12 hr.  In 
KO1/2 cells, 0 hr vs. 6, 18, and 24 hr showed no significant down-regulation. 0 hr vs. 12 
hr was significant (p<.001) indicating a maximal down-regulation of ~ 30% at 12 hr. 
Statistical analysis was done using paired t-tests, (n = 4). B. Time-course in MEF KO1 (n 
= 4) and MEF KO2 (n = 6) cells.  0 hr vs. 6 hr was significant in both KO1 and KO2 and 
individual time points were not significant to each other by a paired t-test.  The maximal 
down-regulation in both KO1 and KO2 was ~50% at 12 hr.  All values represent Mean + 
standard error of the mean (SEM).    p< 0.05 vs. time = 0  
 vi
 
Figure 2. Rescue of M1 mAChR down-regulation in MEF KO1/2 with β-arrestin 1 
or 2.  MEF KO1/2 cells were transiently transfected with eGFP-M1mAChR and either 
empty vector, pcDNA3.1 β-arrestin1, or pcDNA3.1 β-arrestin 2. Cells were treated for 12 
hr with 1 mM carbachol at 24 hr after transfection. Down-regulation was determined by 
measuring the binding of the membrane permeable muscarinic antagonist [3H]-L-
quinuclidinyl benzilate (QNB).   The number of receptors remaining following 
stimulation as compared to number of receptors from non-stimulated controls determined 
the percent down-regulation.  β-arr 1 untreated vs. β-arr 1 with 12 hr 1mM carbachol 
treatment is significant (†p<0.001).  β-arr 2 untreated vs. β-arr 2 with 12 hr 1mM 
carbachol is significant (‡p<0.05).  Significance was determined by paired t-tests. 
Data points represent the Mean + standard error of the mean (SEM) (n = 4).   
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Figure 3. Agonist-induced down-regulation of M1 mAChRs with chimeric,  
 
permanently ubiquitinated β-arrestin in MEF KO1/2.  MEF KO1/2 cells co-
expressing eGFP-M1 mAChR and pcDNA3.1 empty vector, pcDNA3.1-β-arrestin 2 wild 
type (WT) or pEYFP-β-arrestin 2-Ub (chimeric, permanently ubiquitinated β-arrestin 2) 
were stimulated for 12 hr with 1 mM carbachol after the transfection. Down-regulation 
was determined by measuring the binding of the membrane permeable muscarinic 
antagonist [3H]-L-quinuclidinyl benzilate (QNB).   The number of receptors remaining 
following stimulation as compared to number of receptors from non-stimulated controls 
determined the percent down-regulation.  β-arr 2 WT untreated vs. β-arr 2 WT with 12 hr 
1 mM carbachol is significant (p<0.001).  β-arr 2-Ub untreated vs. β-arr 2-Ub with 12 hr 
1mM carbachol is significant (p<0.05).  Data points represent the Mean + standard error 
of the mean (SEM) (n = 6).   
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Figure 4.  Agonist-induced down-regulation of M1 mAChRs with mutated β-arrestin 
in MEF KO1/2.  MEF KO1/2 cells co-expressing eGFP-M1 mAChR and either FLAG-
β-arrestin 2 wild type, FLAG-β-arrestin 2K11R,K12R, or FLAG-β-arrestin 
2K18R,K107R,K108R,K207R, K296R were stimulated for 12 hr with 1 mM carbachol 24 hr after 
transfection.  Down-regulation was determined by measuring the binding of the 
membrane permeable muscarinic antagonist [3H]-L-quinuclidinyl benzilate (QNB).   The 
number of receptors remaining following stimulation as compared to number of receptors 
from non-stimulated controls determined the percent down-regulation. Data points 
represent the Mean + standard error of the mean (SEM)(n = 2). Untreated vs. 12h 1mM 
Carb treated was significantly down-regulated with β-arrestin 2 wild type (†p<0.05).  
Untreated vs. 12h 1mM Carb treated was significantly down-regulated with β-arrestin 2 
C-mutant (*p<0.05).  Untreated vs. 12h 1mM Carb treated was significantly down-
regulated with β-arrestin 2K11R,K12R (‡p<0.05).   
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Figure 5.  Scaffolding function of β-arrestin 1.  The crystal structure of β-arrestin 1 
allows for modeling critical binding sites for proteins such as clathrin, adaptor protein 
(AP2), and GPCR.  These sites on β-arrestin suggest the scaffolding function of arrestin 
proteins.   
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Figure 6.  The proposed model for the role of β–arrestin in the post-translational 
down-regulation of M1 mAChR.  Following agonist binding to the receptor, G proteins 
dissociate and the receptor is phosphorylated by several different kinases on the 3rd 
intracellular loop.  β–arrestin is recruited to the phosphorylated receptor, which stops 
further G protein signaling causing desensitization of the receptor.  β–arrestin dependent 
internalization follows desensitization.  The receptor is then fated for either 
resensitization or down-regulation.  Down-regulation leads to long-term attenuation of 
receptor signaling.     
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Table 1 
mAChR subtypes based on tissue distribution, G-protein coupling, and function   
 
 
  
M1 M2 M3 M4 M5
Distribution Cortex, hippocampus Heart 
Exocrine 
glands, GI 
tract 
Neostriatum Substantia nigra 
G protein Gαq/11 Gαi/o Gαq/11 Gαi/o Gαq/11 
Intracellular 
response 
PLC β 
activation 
Adenylyl 
cyclase 
inhibition 
PLC β 
activation 
Adenylyl 
cyclase 
inhibition 
PLC β 
activation 
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INTRODUCTION 
 
Muscarinic acetylcholine receptors (mAChRs) are divided into five subtypes designated 
as M1- M5 (Table 1).  As members of the super family of GPCRs, mAChRs couple to 
downstream effectors via the interaction with heterotrimeric G proteins.  M1, M3 and M5 
couple to Gαq/11 and G α13, and M2, M4 subtypes couple to Gi and Go.  Stimulation of 
phosphatidylinositol 4,5-bisphosphate (PIP2)-hydrolyzing phospholipase C (PLC) is a 
major signal transduction system used by a wide variety of membrane receptors to 
regulate various cellular functions (Evellin, Nolte et al. 2002).  Upon activation of the M1 
mAChR, the PLC β isoform is activated (see Table 1).  M1 mAChRs regulate cholinergic 
transmission in the hippocampus, which is involved with cognition and memory.  They 
relay information from extracellular stimuli into the cell and therefore must be tightly 
regulated.  The neurotransmitter, acetylcholine, is the only external signal for receptor 
activation.  Regulation of mAChRs is possible at any of the five trafficking events 
following agonist stimulation:  agonist binding causes G protein dissociation from the 
receptor, phosphorylation of key serine and threonine residues on the intracellular loops 
of the receptor by various kinases, β-arrestin binding to cause desensitization and 
internalization of the receptor, and either recycling to the plasma membrane or targeting 
of the receptor for degradation in proteosomes or lysosomes (Fig. 6).  Several kinases 
have been implicated in the phosphorylation of the M1 mAChR.  Casein kinase 1α (CK1 
α ) has been shown to phosphorylate the M1 mAChR in an agonist dependent manner 
(Waugh, Challiss et al. 1999).  CK1 α is constitutively active, but can also be activated by 
calcineurin.  G protein-coupled receptor kinase 2 (GRK 2) phosphorylates the M1 
mAChR (Willets, Nahorski et al. 2005) upon activation by free Gβγ subunits.  Protein 
 1
kinase C (PKC) is activated by inositol 1,4,5 trisphosphate (IP3) and diacylglycerol and 
has also been indicated for the phosphorylation of the M1 mAChR.  The third 
intracellular loop of the M1 mAChR seems to be the site where phosphorylation by these 
kinases occurs (Malatynska, Waite et al. 1998).   
     The identification of key players involved in the trafficking and regulation of M1 
mAChRs is very important.  Over the years, β-arrestin has proven to be one such key 
player starting with the finding that it mediates desensitization of GPCRs.  Evidence has 
accumulated from several laboratories that β-arrestin interacts with clathrin and clathrin-
associated adaptor protein (AP-2), which indicates β-arrestin’s role in clathrin-dependent 
endocytosis of activated β2-adrenergic receptors (Laporte, Oakley et al. 2000).  Following 
internalization, β-arrestins also have been observed operating as scaffold proteins by 
interacting with cellular machinery (Lefkowitz and Shenoy 2005).  Figure 5 shows the 
crystal structure of β-arrestin and these critical binding sites.   
     GPCRs have been placed in two classes of receptors based on their interactions with 
β-arrestin.  β2AR, dopamine 1A receptor, and endothelin type A receptor belong to the 
Class A receptors, and are characterized by rapid recycling and quick dissociation from 
β-arrestin before receptor internalization (Shenoy and Lefkowitz 2005). Class B 
receptors, including the vasopressin 2 receptor (V2R), angiotensin receptor (AT1aR), and 
neurotensin 1 receptor, recycle more slowly and internalize in a stable association with β-
arrestin (Shenoy and Lefkowitz 2005).  Recent work has indicated that the division of 
Class A and B receptors seems to be linked to the ubiquitination status of β-arrestin 
(Shenoy and Lefkowitz 2005).  Class A receptors do not internalize with β-arrestin, and 
they are associated with transient agonist mediated ubiquitination of β-arrestin.  Agonist 
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mediated activation of Class B receptors results in a sustained ubiquitination of β-arrestin 
(Shenoy and Lefkowitz 2005).  Our lab has found stable co-localization of M2 mAChR 
with β-arrestin in early endosomes following internalization indicating that the M2 is a 
Class B receptor. 
     Ubiquitination is classically known for its role in targeting proteins for degradation by 
the proteosome (Hochstrasser 1996).  However, recent work by Lefkowitz indicates a 
much more complex role for ubiquitin regarding receptor trafficking.  Ubiquitin is a small 
regulatory protein that is 8.5 kD and is ubiquitously expressed in all mammalian cells.  
Ubiquitination is the post-translational modification of a protein by the covalent linking 
of the C-terminal glycine of a single 76-residue polypeptide ubiquitin molecule to a 
lysine residue of the substrate protein (Ciechanover, Orian et al. 2000).  
Monoubiquitination involves the attachment of one ubiquitin monomer to the substrate 
protein, whereas polyubiquitination is the attachment of four or more ubiquitin molecules 
to the substrate.  Polyubiquitination tags the protein for degradation, and 
monoubiquitination may involve targeting within the cell.  The attachment of ubiquitin to 
substrate proteins is carried out by an ATP-dependent mechanism that is catalyzed by the 
sequential activity of three enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-
conjugating (UBC) enzymes (E2s), and ubiquitin ligases (E3s) (Marchese, Raiborg et al. 
2003).  The E3s recognize the substrate protein and therefore are important for 
specificity.  Mouse double minute 2 (Mdm2) is the E3 ubiquitin ligase that constitutively 
associates with β-arrestin and ubiquitinates it (Shenoy, McDonald et al. 2001).  
     Four functional members of the arrestin gene family have been cloned (Freedman and 
Lefkowitz 1996; Ferguson 2001).  Two arrestins, visual arrestin (Shinohara, Dietzschold 
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et al. 1987; Yamaki, Takahashi et al. 1987) and cone arrestin (Murakami, Yajima et al. 
1993), are expressed mostly in the retina and regulate photoreceptor function.  The β-
arrestins, β-arrestin 1(Lohse, Benovic et al. 1990) and β-arrestin 2 (Attramandal et al., 
1992), are ubiquitously expressed proteins with their highest level of expression found in 
the brain and spleen.  β-arrestin 1 has 35 lysine residues and β-arrestin 2 has 31(Shenoy 
and Lefkowitz 2005).  β-arrestin 2’s lysine residues 18, 107, 108, 207 and 296 were 
found to be critical in the internalization and down-regulation of Class B receptors.  
Lysine residues 11 and 12 were not involved with the internalization or down-regulation.   
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HYPOTHESIS AND SPECIFIC AIMS 
We hypothesize that agonist-induced down-regulation of M1 mAChR is mediated by 
transient ubiquitination of β-arrestin, which subsequently sorts the mAChR subtype to 
lysosomal/proteosomal degradation.  The goal of this project was to better characterize 
the M1 mAChR subtype specifically.  Therefore, we proposed the following Specific 
Aims. 
Specific Aim 1.  To determine whether expression of YFP-β-arrestin2-Ub enhances 
agonist-promoted down-regulation of M1 mAChR: 
Use co-expression of M1 mAChR and YFP-βarr2-Ub combined with radioligand binding 
to determine whether a stable chimeric ubiquitinated β-arrestin enhances agonist-
promoted down-regulation in M1 mAChRs. 
Experimental Design for Specific Aim 1: 
A. Co-express M1 and YFP-β-arrestin-Ub in MEF KO1/2 cells  
B. Stimulate with carbachol for 12 hr (time point of maximal down-regulation) 
C. Perform radioligand binding assay with crude membrane homogenates 
D. Compare to the down-regulation found with no β-arrestin (empty vector; pcDNA3) or 
β-arrestin 2 
Specific Aim 2.  To determine whether expression of β-arrestin 2 mutants lacking 
selective putative ubiquitination sites attenuates agonist-promoted down-regulation 
of M1 mAChRs. 
A.  Use co-expression of eGFP M1 mAChR with β-arrestin2 K11R,K12R or  
β-arrestin2K18R,K107R,K108R,K207R,K296R combined with radioligand binding to examine 
whether agonist-promoted down-regulation is attenuated. 
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Experimental Design for Specific Aim 2: 
A. Co-express M1 and β-arrestin 2K11R,K12R or β-arrestin 2K18R,K107R,K108R,K207R,K296R in 
MEF KO1/2 cells (use these cells because endogenous β-arrestin would interfere with the 
effect) 
B. Perform radioligand binding assay with crude membrane homogenates and compare 
the down-regulation with mutant β-arrestin to the down-regulation with no β-arrestin 
(pcDNA3) or β-arrestin 2 wild type. 
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MATERIALS AND METHODS 
Cell Culture and Transient Transfection 
     Lefkowitz’s group had previously prepared mouse embryonic fibroblasts from 
knockout mice that lack one of the β-arrestins (β-arrestin 1-KO and β-arrestin 2-KO) or 
both (β-arrestin 1/2-KO), as well as their wild-type (WT) littermate controls (cells from 
Dr. Robert Lefkowitz at Duke University Medical Center, Durham, NC). 
     Mouse embryonic fibroblasts and these described knock out cell lines were maintained 
in growth medium containing the following components:  Dulbecco’s modification of 
Eagle’s medium (DMEM, Mediatech) supplemented with 10% fetal bovine serum (FBS, 
Invitrogen), and 0.05% penicillin/streptomycin (P/S, Invitrogen).  All cells were grown in 
an incubator at 37oC with 5% CO2.   
     Twenty-four hours prior to transfection, 1.5x105 cells per well were plated on 6-well 
plates in growth medium without any P/S antibiotic.  Cells were transiently transfected 
using Lipofectamine 2000 reagent (Invitrogen) with 5 µg total DNA per well.  The 
composition of the DNA in each well consisted of 2.5 µg of the M1 receptor and 2.5 µg 
of one of the various forms of β-arrestin as described below.  The expression constructs 
used in the transfections were all purified using the PureLink HiPure Plasmid Maxiprep 
Kits (Invitrogen).  Plasmids included:  pCEP4-eGFP-M1 mAChR, pcDNA3.1 FLAG-
tagged β-arrestin 1 and 2, pEYFP- β-arrestin-Ub, pcDNA3.1 β-arrestin 2K11R,K12R, 
pcDNA3.1 β-arrestin 2K18R,K107R,K108R,K207R, K296R.  All of the MEF cell lines as well as the 
mentioned expression constructs were generous gifts from Dr. Robert Lefkowitz (Duke 
University Medical Center, Durham, NC).   
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     Four hours following the transfection, the antibiotic free media plus Lipofectamine 
2000 reagent was removed and replaced with fresh complete DMEM.  Twenty-four hours 
later the transfection efficiencies were determined using an Olympus 1X71 microscope to 
visualize green fluorescence indicating the presence of the eGFP tag on the M1 mAChR.   
Crude Membrane Preparation 
The 6-well plates were immediately placed on ice and rinsed two times with ice cold 
PBS.  Cells from two wells were scraped into ice cold 50 mM sodium phosphate pH 7.0 
(Sigma Aldrich) and homogenized using 20 strokes in a Dounce homogenizer.  
Homogenates were placed in the appropriate 14 mL polypropylene tubes (Falcon 
352059) and spun at 10,000 rpm for 20 minutes at 4oC in a Sorvall Mach 1.6R fixed 
angle rotor.  Pellets were resuspended in 550 µL 50 mM sodium phosphate pH 7.0 and 
used for BCA protein assay (Pierce) and radioligand binding.   
BCA Protein assay 
The BCA Protein Assay Kit was purchased from Pierce and was used to determine the 
protein concentration in the crude membrane samples.  This method is based on 
bicinchoninic acid (BCA) for colorimetric detection and quantitation of total protein.  
When two molecules of BCA chelate one cuprous ion, a water soluble purple-colored 
reaction product is created and it has a strong absorbance at 562 nm.  This absorbance is 
linear with increasing protein concentrations in the range of 20-2,000 µg/mL.  Protein 
concentrations were determined with reference to a standards made up with the protein 
bovine serum albumin (BSA).  The standards were made with increasing concentrations 
of BSA diluted in the same buffer the unknown proteins were prepared in; 50mM sodium 
phosphate buffer pH 7.0.  Ten µL of each standard solution was added to three wells each 
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of a 96-well plate.  Ten µL per well of each unknown protein solution was added to three 
wells each next to the standards.   
     Two hundred µL of the BCA regent was added to each well and the 96-well plate was 
incubated for 30 minutes at 37 o C.  A VERSAmax microplate reader measured the 
absorbances at 562 nm.  These absorbances were converted to milligrams of protein per 
milliliter volume.   
Radioligand Binding 
Down Regulation- Quinuclidinyl benzilate (QNB) is a lipophilic membrane permeable 
muscarinic antagonist. QNB’s permeable nature allows for binding both receptors on the 
surface as well as internalized receptors.  Radiolabeled QNB was purchased from 
Amersham Corp. (Buckinghamshire, England).  Down-regulation was determined by 
measuring the binding of the membrane permeable muscarinic antagonist [3H]-L-
quinuclidinyl benzilate (43 Ci/mmole).   The number of receptors remaining following 
stimulation as compared to number of receptors from non-stimulated controls determined 
the percent down-regulation. 100 µL crude membranes were incubated with 30 nM [3H]-
L-quinuclidinyl benzilate in a total volume of 1 mL 50 mM sodium phosphate pH 7.0 for 
one and a half  hours at room temperature .  Nonspecific binding was determined as the 
bound radioactivity in the presence of 1 µM atropine.  A Brandell cell harvester 
(Gaithersburg, MD) collected the membranes on glass filters and washed them 3 times, 2 
mL each with ice cold 50 mM sodium phosphate pH 7.0.  Filter discs were combined 
with 3.5 mL scintillation fluid and incubated for at least 2 hours prior to measuring the 
amount of radioactivity.  The scintillation counter (Beckman Coulter LS 6500) printout 
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showed the average counts per minute for a given sample. Cpm were converted to pmoles 
receptor using the following equation:   
specific cpm = average cpm – average cpm in the presence of atropine 
specific cpm/tube x dpm/0.37 cpm x 1 Ci/2.22x1012 dpm x 1 mmole/43Ci x 1 
mole/1000 mmole x 1x1012 pmole/mole 
     These numbers were then corrected to milligrams of total protein per tube using values 
from the BCA assay.  Percent down-regulation was determined as percent of sites 
remaining compared to untreated control membranes.    
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RESULTS 
     To examine whether ectopically expressed M1 mAChR undergo agonist-promoted 
down-regulation, MEF wild type and corresponding β-arrestin null cells were transiently 
transfected with eGFP-tagged human M1 mAChR.  Following 24 hr transfection, MEF 
wild type, MEF KO1, MEF KO2 and MEF KO1/2 were stimulated with 1 mM carbachol 
for 6, 12, 18, and 24 hr at 37◦ C.  Down-regulation was determined by measuring the 
binding of the membrane permeable muscarinic antagonist [3H]-L-quinuclidinyl benzilate 
(QNB).   The number of receptors remaining following stimulation as compared to 
number of receptors from non-stimulated controls determined the percent down-
regulation.   
     In MEF wild type cells, M1 mAChRs were maximally down-regulated by ~50% at 12 
hr (Fig. 1A).  The 12 hr time point was not significantly different from the 18 hr time 
point.  The MEF KO1/2 cells had a maximal down-regulation at 12 hr (Fig. 1A).  In 
contrast, M1 mAChRs at 6, 18, and 24 hr did not undergo any significant down-
regulation.  However, at 12 hr of stimulation, M1 mAChRs showed ~30% down-
regulation (Fig. 1A).  M1 mAChRs were maximally down-regulated at 12 hr (50%) when 
they were expressed in both MEF KO1 and MEF KO2 (Fig. 1B).  Overall, these time 
courses indicate that 12 hr is sufficient for maximal down-regulation of the M1 mAChRs 
for all four cell lines.  Therefore, the 12 hr stimulation time point was chosen for 
additional down-regulation experiments.   
     To establish the dependency of down-regulation on β-arrestin isoforms, MEF KO1/2 
cells were transiently transfected with the M1 mAChR and either empty vector or 
pcDNA3.1 β-arrestin1, or with either pcDNA3.1 (empty vector) or pcDNA3.1 β-arrestin 
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2.  Cells were treated for 12 hr with 1 mM carbachol at 24 hr after transfection.  Down-
regulation was determined by measuring the binding of the membrane permeable 
muscarinic antagonist [3H]-L-quinuclidinyl benzilate (QNB).  The number of receptors 
remaining following stimulation as compared to number of receptors from non-stimulated 
controls determined the percent down-regulation. The down-regulation of M1 mAChR 
could be rescued in the MEF KO1/2 cells with either β-arrestin 1 or β-arrestin 2 (Fig. 2).     
     To determine whether M1 mAChRs fall into Class A or Class B receptors it is 
necessary to find out if β-arrestin is transiently ubiquitinated (Class A) or stably 
ubiquitinated like in Class B receptors (Oakley, Laporte et al. 2000).  This experiment 
will be covered in the Future Research section.   
     In order to determine the role of ubiquitination in the agonist induced down-regulation 
of M1 mAChRs, a constitutively ubiquitinated β-arrestin was used.  The chimera contains 
ubiquitin which is fused to the C-terminus and yellow fluorescent protein (YFP) which is 
fused to the N-terminus.  MEF KO1/2 cells co-expressing pCEP4-eGFP-M1 mAChR and 
pcDNA3.1 empty vector, pcDNA3.1-β-arrestin 2 (wild type) or YFP-β-arrestin 2-Ub 
were stimulated for 12 hr with 1 mM carbachol 24 hr after the transfection.  Down-
regulation was determined by measuring the binding of the membrane permeable 
muscarinic antagonist [3H]-L-quinuclidinyl benzilate (QNB). The number of receptors 
remaining following stimulation as compared to number of receptors from non-stimulated 
controls determined the percent down-regulation.  15% agonist independent constitutive 
down-regulation occurred in the presence of β-arrestin 2 wild type (WT) and the down-
regulation increased to 60% following agonist stimulation (Fig. 3).  The constitutively 
ubiquitinated β-arrestin 2 facilitated a 52% reduction of total receptors even in the 
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absence of agonist, and this receptor down-regulation increased to 72% with agonist 
stimulation (Fig. 3).  Agonist stimulation significantly increased the percent down-
regulation in the presence of β-arrestin 2 WT and β-arrestin 2-Ub in addition to the 
apparent constitutive effect with the addition of β-arrestins alone. These data indicate that 
ubiquitination of β-arrestin does indeed play a role in the constitutive and agonist-
induced down-regulation of the M1 mAChR. 
     Because the ubiquitination of β-arrestin obviously plays a role in receptor down-
regulation, another step was taken to further elucidate the mechanism.  Specific lysine 
residues on β-arrestin were mutated to determine which lysines were crucial sites of 
ubiquitination. The lysines (K) were mutated to arginines (R) in the “C” mutant (5 
mutated residues) and the K11, 12R mutant (2 mutated residues).  FLAG-β-arrestin 
2K11R,K12R MEF KO1/2 cells co-expressing pCEP4-eGFP-M1 mAChR and either FLAG-
β-arrestin 2 wild type, FLAG-β-arrestin 2K11R,K12R, or FLAG-β-arrestin 
2K18R,K107R,K108R,K207R, K296R were stimulated for 12 hr with 1 mM carbachol 24 hr after 
transfection.  Down-regulation was determined by measuring the binding of the 
membrane permeable muscarinic antagonist [3H]-L-quinuclidinyl benzilate (QNB).   The 
number of receptors remaining following stimulation as compared to number of receptors 
from non-stimulated controls determined the percent down-regulation.  As shown in Fig. 
4, β-arrestin 2 wild type significantly down-regulates the M1 mAChR (~30%) following 
12 hr agonist stimulation.  β-arrestin 2 with two mutated lysine residues (11, 12) does not 
interfere with down-regulation, but rather facilitates down-regulation (~35%) in a similar 
fashion as the wild type β-arrestin 2.  The β-arrestin 2 C mutant still allows for significant 
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down-regulation following agonist stimulation.  Since this figure was made from only 
one data set, further experiments will be necessary to confirm these results. 
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DISCUSSION 
      M1 mAChRs undergo down-regulation following agonist stimulation.  The MEF 
knockout mice cell lines worked well for studying the actions of the M1 receptors.  MEF 
wild type cells contain both isoforms of β-arrestin and 12 hr was sufficient for maximal 
down-regulation of the M1 mAChR (Fig. 1A).  The MEF KO1/2 showed down-regulation 
only at 12 hr (Fig. 1A).  This was particularly surprising due to the fact that MEF KO1/2 
do not contain either isoforms of β-arrestin.  In contrast, M1 mAChRs at 6, 18, and 24 hr 
did not undergo any significant down-regulation.  However, at 12 hr of stimulation, M1 
mAChRs were down-regulated by 30% (Fig. 1A).  The 12 hr time point may indicate that 
some β-arrestin independent down-regulation pathways are activated, but more likely it is 
due to some experimental error.  This position is sustained by the fact that the MEF 
KO1/2 cells did show any significant down-regulation at any other time point.             
Interestingly, M1 mAChRs were significantly down-regulated at 6 hr in both MEF KO1 
and MEF KO2, with maximal down-regulation (50%) of M1 mAChR occurring at 12 hr 
following agonist stimulation (Fig. 1B).  MEF KO1 and MEF KO2 have similar time 
courses of down-regulation and therefore M1 mAChRs do not appear to have any 
selectivity for either β-arrestin 1 or 2 isoforms.  Overall, these time courses indicate that 
12 hr is sufficient for maximal down-regulation of the M1 mAChRs for all four cell lines.  
Therefore, the 12 hr stimulation time point was chosen for additional down-regulation 
experiments. 
     The ability of either β-arrestin isoform to rescue the down-regulation in MEF KO1/2 
demonstrates how critical arrestin is for the process of down-regulation.  MEF KO1/2 
cells do not express either isoform of β-arrestin, and therefore expressed M1 mAChR are 
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unable to undergo down-regulation. Co-expression of M1 mAChR with either β-arrestin 1 
or β-arrestin 2 restores the down-regulating capability (Fig. 2).     
     Ubiquitination of β-arrestin does play a role in this down-regulation of M1 mAChR. 
The chimeric, constitutively ubiquitinated β-arrestin facilitated an enhanced down-
regulation of the receptors following agonist stimulation (Fig. 3).  The enhanced down-
regulation was not agonist dependent, but was further increased after the agonist was 
added.  A large constitutive effect occurred with the addition of β-arrestin 1 or 2 even in 
the absence of agonist stimulation.  This could be explained in several ways.  The 
addition of β-arrestin was achieved by transiently transfecting in either isoform of β-
arrestin.  The constitutive down-regulation could be due to excess β-arrestin compared to 
the number of receptors available.  The M1 receptor has a bulky GFP tag on its N-
terminus and may have lower expression in the presence of β-arrestin DNA.  
Internalization of the receptors is β-arrestin dependent, so the constitutive effect that 
occurs when either β-arrestin is over-expressed may be due to enhanced internalization 
followed by a more down-regulation.   
     Ubiquitination has been known to target proteins for degradation, and recently has 
been noted for having novel roles in targeting and signaling within the cell (Shenoy and 
Lefkowitz 2005).  Since ubiquitination does play a role in the down-regulation of M1 
receptors, lots of exciting opportunities await for discovering more about how these 
receptors signal even after they are inside the cell.  Ubiquitination occurs at key lysine 
residues on the substrate protein.  For the case of the arrestin acting as a substrate protein,  
β-arrestin 1 has 35 and β-arrestin 2 has 31 lysine residues which are potential sites for 
ubiquitination (Shenoy and Lefkowitz 2005).  The activated M1 mAChR may bind β-
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arrestin which then opens up a unique combination of lysine residues for ubiquitination.  
Then the receptor can be targeted accordingly.   
     Specific lysine residues on β-arrestin were mutated to determine which lysines were 
crucial sites of ubiquitination.  This information will be important to determine exactly 
where β-arrestin is ubiquitinated.  As shown in Fig. 4, the β-arrestin 2 wild type 
significantly down-regulates the M1 mAChR following 12 hr agonist stimulation.  The β-
arrestin 2 with two mutated lysine residues (11, 12) does not interfere with down-
regulation, but rather facilitates down-regulation in a similar fashion as the wild type β-
arrestin 2.  The β-arrestin C mutant at a glance still allows for significant down-
regulation of the M1 mAChR, but more replicates of this experiment are needed to 
determine if this observation is true.  These experiments will help narrow down which 
lysine residues are getting ubiquitinated.  The two β-arrestin mutants chosen may not 
have the correct lysine residues mutated.  Since β-arrestin 1 has 35 and β-arrestin 2 has 
31 lysine residues, ubiquitination could be occurring at other lysine residues.   
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Summary of my contributions
     I determined that 12 hr of agonist stimulation is sufficient for the maximal down-
regulation of the M1 mAChR in MEF WT, KO1 and KO2 cells.  The M1 mAChR does 
not have any selectivity for either β-arrestin 1 or β-arrestin 2.   
     β-arrestin-Ub enhances the agonist-induced down-regulation of the M1 mAChR, 
which gives the first evidence that ubiquitination plays a role in the down-regulation of 
M1.   
     The β-arrestin 2 K11,12R and C mutants do not block the agonist-induced down-
regulation of M1 mAChR.  These experiments must be repeated before these lysine 
residues are ruled out as important sites for ubiquitination.   
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Future Research 
 
     Determine whether activation of M1 mAChRs by agonist increases ubiquitination of 
β-arrestin. Use co-expression of FLAG-β-arrestin 2 and Ub-GFP combined with 
immunoprecipitation to determine whether agonist stimulation of M1 mAChR increases 
ubiquitination of β-arrestin.  Visualizing the time course of the ubiquitination of β-
arrestin will help determine if the M1mAChR is a Class A or B receptor. 
     Another way to show agonist stimulation increases ubiquitination of β-arrestin: Use 
co-expression of FLAG-βarrestin and Ub-GFP combined with ICC to determine whether 
agonist stimulation of HA-M1 mAChR increases ubiquitination of β-arrestin. 
     Yet another method that still needs to be finely tuned. The co-expression of β-arrestin-
luciferase and Ub-GFP combined with BRET analysis can also be used to determine 
whether agonist stimulation of M1 mAChR promotes the association between ubiquitin 
and β-arrestin. 
Experimental Design for these experiments: 
Western blot 
a. Use Chinese hamster ovary (CHO) cells stably expressing M1 mAChR (human) on 6-
well plates. 
b. Transfect cells with both FLAG-β-arrestin 2 and Ub-GFP. 
c. Stimulate with agonist (carbachol) for 0, 1, 3, 15, 30 minutes prior to cell lysis. 
d. Immunoprecipitate with FLAG antibody and immunoblot with GFP antibody.  
Note: This time course of stimulation was chosen because Class A receptors show a rapid 
ubiquitination of β-arrestin at 1 min, which decreases by 15 min.  Class B receptors 
ubiquitination of β-arrestin is seen at 15 min and it is stable by 30-60 min.   
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Immunocytochemistry (ICC) 
a. Co-express FLAG-βarr and Ub-GFP in CHO cells stably expressing M1mAChR 
b. Stimulate with agonist at 0, 1, 3, 15, 30 min  
c. Fix cells and stain with fluorescent Texas red antibody 
d. Co-localization indicates ubiquitination of β-arrestin   
Bioluminescence resonance energy transfer (BRET) 
a. Use CHO M1 cells in plates suitable for luminescence and fluorescence. Provide 
luciferin and analyze the ratio of luminescence/fluorescence (if energy is transferred, 
luminescence decreases). 
     Another area needed to be addressed is whether or not the β-arrestin mutants prevent 
internalization of the receptor.  Perform radioligand binding with intact cells and 
membrane impermeable muscarinic antagonist, [3H]-N-methyl scopolamine.  This ligand 
only binds surface receptors. 
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